Immediate Impact

58 standout
Sub-graph 1 of 23

Citing Papers

Cancer associated fibroblasts in cancer development and therapy
2025 Standout
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
2024 Standout
1 intermediate paper

Works of D. Xing being referenced

Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
2018
Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)
2018

Author Peers

Author Last Decade Papers Cites
D. Xing 102 232 50 278 170 10 442
Hill Cs 125 141 41 345 69 10 499
Hickey Rc 117 116 41 282 76 13 397
Margareta Telenius‐Berg 87 147 18 272 65 14 429
Kathy Liu 29 190 13 113 104 15 408
Sylvie Beaudenon‐Huibregtse 38 129 21 402 134 9 458
B.B. Jacobsen 76 90 17 103 143 9 379
Ruth E. Farrell 106 140 15 343 36 8 457
Usha Sriram 164 53 25 103 159 12 421
Yedatore Venkatesh 116 107 23 275 96 10 382
Annalisa Montanaro 43 201 22 419 109 8 500

All Works

Loading papers...

Rankless by CCL
2026